3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Phase 2
1
Status
Completed
2
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
beta-Thalassemia
1
Myelodysplastic Syndromes
1
Anemia
1
Interventions
Cyclophosphamide
299
Cisplatin
298
Paclitaxel
257
Radiotherapy
255
Fluorouracil
234
Carboplatin
234
Docetaxel
230
Doxorubicin
216
Dexamethasone
166
Gemcitabine
156
Vincristine
147
Etoposide
136
Leucovorin
133
Capecitabine
129
Bevacizumab
129
Prednisone
125
Rituximab
118
Methotrexate
118
Cytarabine
110
Filgrastim
99
Trastuzumab
97
Oxaliplatin
96
pembrolizumab
83
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Daunorubicin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
luspatercept
×
Clear all
NCT02604433
2023-04-18
BELIEVE
Celgene
Phase 3
Completed
336 enrolled
38 charts
1 FDA
NCT02631070
2021-12-17
MEDALIST
Celgene
Phase 3
Completed
229 enrolled
36 charts
1 FDA